Lisata Therapeutics (LSTA) Competitors $2.71 +0.19 (+7.54%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends LSTA vs. PWUP, ME, CTMX, ANL, KPTI, RVPH, QNCX, ALXO, PMVP, and GNLXShould you be buying Lisata Therapeutics stock or one of its competitors? The main competitors of Lisata Therapeutics include PowerUp Acquisition (PWUP), 23andMe (ME), CytomX Therapeutics (CTMX), Adlai Nortye (ANL), Karyopharm Therapeutics (KPTI), Reviva Pharmaceuticals (RVPH), Quince Therapeutics (QNCX), ALX Oncology (ALXO), PMV Pharmaceuticals (PMVP), and Genelux (GNLX). These companies are all part of the "pharmaceutical products" industry. Lisata Therapeutics vs. PowerUp Acquisition 23andMe CytomX Therapeutics Adlai Nortye Karyopharm Therapeutics Reviva Pharmaceuticals Quince Therapeutics ALX Oncology PMV Pharmaceuticals Genelux Lisata Therapeutics (NASDAQ:LSTA) and PowerUp Acquisition (NASDAQ:PWUP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, community ranking, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings. Does the media favor LSTA or PWUP? In the previous week, Lisata Therapeutics' average media sentiment score of 0.00 equaled PowerUp Acquisition'saverage media sentiment score. Company Overall Sentiment Lisata Therapeutics Neutral PowerUp Acquisition Neutral Is LSTA or PWUP more profitable? PowerUp Acquisition's return on equity of 0.00% beat Lisata Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lisata TherapeuticsN/A -51.19% -45.16% PowerUp Acquisition N/A N/A N/A Do analysts rate LSTA or PWUP? Lisata Therapeutics presently has a consensus price target of $15.00, suggesting a potential upside of 453.51%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Lisata Therapeutics is more favorable than PowerUp Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00PowerUp Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, LSTA or PWUP? Lisata Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, PowerUp Acquisition has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500. Do insiders and institutionals have more ownership in LSTA or PWUP? 8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 19.2% of PowerUp Acquisition shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 48.0% of PowerUp Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, LSTA or PWUP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLisata TherapeuticsN/AN/A-$20.84M-$2.51-1.08PowerUp AcquisitionN/AN/AN/AN/AN/A Does the MarketBeat Community favor LSTA or PWUP? Lisata Therapeutics received 14 more outperform votes than PowerUp Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformLisata TherapeuticsOutperform Votes1493.33% Underperform Votes16.67%PowerUp AcquisitionN/AN/A SummaryLisata Therapeutics beats PowerUp Acquisition on 5 of the 9 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Lisata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSTA vs. The Competition Export to ExcelMetricLisata TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.75M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-1.0810.5990.0517.20Price / SalesN/A196.061,117.09117.04Price / CashN/A57.1643.1037.85Price / Book0.465.094.784.78Net Income-$20.84M$151.83M$120.31M$225.60M7 Day Performance5.04%-2.14%-1.92%-1.23%1 Month Performance-5.90%-4.56%13.65%0.46%1 Year Performance-4.24%8.87%28.34%15.24% Lisata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSTALisata Therapeutics1.8987 of 5 stars$2.71+7.5%$15.00+453.5%-4.9%$22.75MN/A-1.0830PWUPPowerUp AcquisitionN/A$11.43flatN/A+1.6%$88.81MN/A0.00N/AME23andMe2.3629 of 5 stars$3.40+1.5%$9.40+176.5%-80.8%$88.81M$219.64M-0.13770Positive NewsCTMXCytomX Therapeutics4.3268 of 5 stars$1.12+0.9%$5.77+415.4%-22.7%$87.65M$101.21M6.53170News CoveragePositive NewsANLAdlai Nortye1.583 of 5 stars$2.36+3.1%$9.00+281.4%-75.5%$87.08M$5M0.00127KPTIKaryopharm Therapeutics3.8015 of 5 stars$0.68-3.3%$5.00+638.3%-16.5%$85.46M$148.44M-0.61380RVPHReviva Pharmaceuticals3.0041 of 5 stars$2.53-3.1%$15.50+512.6%-65.2%$84.60MN/A-2.355High Trading VolumeQNCXQuince Therapeutics2.8951 of 5 stars$1.89-6.9%$8.50+349.7%+63.3%$83.16MN/A-1.6460Analyst ForecastAnalyst RevisionNews CoverageALXOALX Oncology3.1952 of 5 stars$1.57+8.3%$10.67+579.4%-87.6%$82.81MN/A-0.4940Analyst ForecastNews CoveragePMVPPMV Pharmaceuticals1.7863 of 5 stars$1.59+0.3%$5.80+265.9%-45.8%$82.02MN/A0.0050Positive NewsGNLXGenelux0.8843 of 5 stars$2.34+0.4%$18.25+679.9%-83.8%$80.82M$8,000.00-2.4510 Related Companies and Tools Related Companies PowerUp Acquisition Competitors 23andMe Competitors CytomX Therapeutics Competitors Adlai Nortye Competitors Karyopharm Therapeutics Competitors Reviva Pharmaceuticals Competitors Quince Therapeutics Competitors ALX Oncology Competitors PMV Pharmaceuticals Competitors Genelux Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LSTA) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
